Dr. Leyman worked for over 11 years in the biotech industry with a focus on building biotech companies, investment strategies and business development. Till recently, Barbara Leyman was the head of the life sciences group at the venture capital fund LRM. As such, she has been extensively involved in assessing and implementing investment opportunities in biotech companies primarily with a focus on innovations in therapeutics. She took active director positions on the board of several biotech companies. She is currently a director at Apitope, a UK-based private clinical stage biopharmaceutical company focused on treating the underlying cause of autoimmune diseases. Apitope’s lead product for the treatment of multiple sclerosis yielded positive results in a Phase IIa clinical study. Before becoming an investor at LRM, Dr. Leyman worked at VIB, the Flanders Biotech Institute in Belgium with a focus on building biotech start-ups and business development. Translation of new inventions into pharmaceutical products was her core activity. She completed over 50 licensing and research deals with pharmaceutical and biotech industry and assisted preparing the launch of new ventures based on innovative life science projects in drug discovery. Dr. Leyman holds an Executive Master degree in entrepreneurship and innovation from the Vlerick Business School, Belgium. She obtained her Ph.D. in 1997 in Imperial College at Wye at the London University, and her master degree Biotechnology and Chemistry at the University of Ghent.